EUVIMEDEUVIMED entdecken
Crossref

Current management of Tenosynovial Giant Cell Tumours of the knee in the United Kingdom

Thomas R W Ward, Robert U Ashford, Nicholas C Eastley

The Knee · 2025

DOI: 10.1016/j.knee.2025.06.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Knee, 2025. Verfasst von Thomas R W Ward und 2 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals of Leicester NHS Trust, United Kingdom. Electronic address: Thomasrwward@doctors.org.uk. Hauptthemen laut MEDLINE: Giant Cell Tumor of Tendon Sheath, Knee Joint. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tenosynovial Giant Cell Tumours (TGCTs) are a group of rare, benign, mesenchymal tumours involving synovium, bursae or tendon sheaths. There are two subtypes of TGCT (nodular (nTGCT) and diffuse (dTGCT)) and the current guidelines on the management of both is limited. METHODS: A questionnaire was distributed to members of the British Orthopaedic Oncology Society to investigate members' management of primary and recurrent TGCT. Respondents were questioned on their chosen radiological investigations, use of biopsy, surgical and oncological management and follow up. Descriptive analysis of the qualitative data was performed through data coding. RESULTS: Eighteen responses were received from orthopaedic consultants subspecialising in sarcoma surgery. One was excluded due to practice outside of the United Kingdom (UK). Magnetic Resonance Imaging (MRI) was unanimously the primary investigation of choice. Biopsy rates varied depending on extent of disease, imaging appearances and MDT input. Most surgeons manage primary and recurrent nodular and diffuse TGCT with an open excision. When surgery is performed by a knee or soft-tissue knee surgeon, excisions were more likely to be performed arthroscopically. A staged resection was most commonly performed for dTGCT. Indications for additional therapies in dTGCT varied between units. Follow up regimens also varied, although unsurprisingly diffuse and recurrent disease were reviewed with increased frequency for a longer duration. DISCUSSION: TGCT is a rare, complex disease that encompasses a range of phenotypes. Despite a recent global consensus meeting, our data shows that TGCT is still investigated, managed, and followed up with great variability across the UK.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Giant Cell Tumor of Tendon SheathKnee JointHumansUnited KingdomMagnetic Resonance ImagingSurveys and QuestionnairesArthroscopyBiopsy

Stichwörter der Autor:innen

KneePVNSPigmented Villonodular SynovitisRecurrenceTGCTTenosynovial Giant Cell Tumour

Autor:innen und Institutionen

  • University Hospitals of Leicester NHS Trust, United Kingdom. Electronic address: Thomasrwward@doctors.org.uk.
  • University Hospitals of Leicester NHS Trust, United Kingdom; East Midlands Sarcoma Service, United Kingdom; The University of Leicester, United Kingdom.

Zitieren

APA

Ward, T. R. W., Ashford, R. U., & Eastley, N. C. (2025). Current management of Tenosynovial Giant Cell Tumours of the knee in the United Kingdom. The Knee. https://doi.org/10.1016/j.knee.2025.06.006

Vancouver

Ward TRW, Ashford RU, Eastley NC. Current management of Tenosynovial Giant Cell Tumours of the knee in the United Kingdom. The Knee. 2025. doi:10.1016/j.knee.2025.06.006

BibTeX
@article{Ward2025,
  author = {Ward, Thomas R W and Ashford, Robert U and Eastley, Nicholas C},
  title = {Current management of Tenosynovial Giant Cell Tumours of the knee in the United Kingdom},
  journal = {The Knee},
  year = {2025},
  doi = {10.1016/j.knee.2025.06.006}
}
Kostenlos starten →